NEW YORK (TheStreet) -- Vericel (VCEL) - Get Report shares are up 8.68% to $3.98 in early market trading on Tuesday following the release of the clinical-stage biotechnology company's fourth quarter earnings results after the closing bell yesterday.

The company, a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions reported a fourth quarter net loss of $2.4 million, or a loss of 17 cents per diluted share, compared to the same period last year when the company reported a net loss of $2.9 million, or a loss of 97 cents per diluted share.

The company reported total net revenues of $14.7 million, including approximately $11.4 million in net sales of its Carticel implants and surgical kits, a 13% increase over the same quarter last year.

Analysts on average were expecting the company to report a net loss of 31 cents per share on revenue of $10.7 million.

TheStreet Ratings team rates VERICEL CORP as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation:

"We rate VERICEL CORP (VCEL) a SELL. This is driven by some concerns, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and generally disappointing historical performance in the stock itself."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

• You can view the full analysis from the report here: VCEL Ratings Report

VCEL

data by

YCharts

Must Read: Warren Buffett's Top 25 Stocks for 2015